Last reviewed · How we verify
V0034CR01B vehicle
Orfagen's V0034CR01B vehicle is a drug that serves as a delivery mechanism for other pharmaceuticals.
At a glance
| Generic name | V0034CR01B vehicle |
|---|---|
| Sponsor | Orfagen |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action for V0034CR01B is not publicly available, but it is likely designed to facilitate the transport of active pharmaceutical ingredients to their target sites in the body.
Approved indications
Common side effects
Key clinical trials
- Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis (PHASE3)
- Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V0034CR01B vehicle CI brief — competitive landscape report
- V0034CR01B vehicle updates RSS · CI watch RSS
- Orfagen portfolio CI